Trials
12 active
16 in total · 10 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-bart: artificial immunoglobulins WHO name stem
- Tested for
- Venous Thromboembolism (VTE) (3 trials), Atrial Fibrillation (AF) (3 trials), Symptomatic Venous Thromboembolism (VTE), Peripheral Artery Disease (PAD), Secondary Stroke, Cancer-Associated Thrombosis (CAT), End-Stage Kidney Disease (ESKD)
- Main trialPhase 3
- “This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement surgery. The aim of the study is to see how effective the study drug is at preventing Venous Thromboembolism (VTE) and other related diseases after total knee replacement surgery. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the…”In the company’s words, NCT07015905 on ClinicalTrials.gov
- Other names
- REGN7508
Other drugs for Venous Thromboembolism (VTE)
- KinisoquinQuercis Pharma AG · Phase 3
- REGN9933Regeneron · Phase 3
- VortosiranRibocure Pharmaceuticals AB · Phase 2
- SRSD107Sirius Therapeutics · Phase 2
- YKYY033Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. · Phase 1
- CITY-FXICity Therapeutics · Phase 1
Coming up12
- 9 Feb 2027Phase 2 trial completes · ClinicalTrials.gov
- 20 Feb 2027Phase 3 trial completes · ClinicalTrials.gov
- 23 Mar 2027Phase 1 trial completes · ClinicalTrials.gov
- 2 Apr 2027Phase 1 trial completes · ClinicalTrials.gov
- 17 May 2027Phase 3 trial completes · ClinicalTrials.gov
- 28 Mar 2029Phase 3 trial completes · ClinicalTrials.gov
- 25 Jun 2029Phase 3 trial completes · ClinicalTrials.gov
- 18 Aug 2029Phase 3 trial completes · ClinicalTrials.gov
- 11 Sep 2029Phase 3 trial completes · ClinicalTrials.gov
- 15 Dec 2029Phase 3 trial completes · ClinicalTrials.gov
- 23 Jan 2030Phase 3 trial completes · ClinicalTrials.gov
- 18 Jul 2031Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials16
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 20 Feb 2027 | REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults | |
| Phase 3Recruiting | 17 May 2027 | REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants | |
| Phase 3Recruiting | 28 Mar 2029 | Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable | |
| Phase 3Recruiting | 25 Jun 2029 | Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants With a Peripherally Inserted Central Catheter (PICC) | |
| Phase 3Recruiting | 18 Aug 2029 | Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease | |
| Phase 3Recruiting | 11 Sep 2029 | Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation | |
| Phase 3Not yet recruiting | 15 Dec 2029 | A Study to Evaluate Cenvacibart (REGN7508) for Secondary Stroke Prevention in Adult Participants | |
| Phase 3Recruiting | 23 Jan 2030 | REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis | |
| Phase 3Recruiting | 18 Jul 2031 | Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers | |
| Phase 2Recruiting | 9 Feb 2027 | Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation | |
| Phase 1Not yet recruiting | 23 Mar 2027 | Healthy Adult Participants Trial Comparing Different Cenvacibart Presentations | |
| Phase 1Recruiting | 2 Apr 2027 | Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on Hemodialysis | |
| Phase 2Completed | 19 Nov 2024 | A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants | |
| Phase 2Completed | 27 Mar 2026 | A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC) | |
| Phase 1Completed | 17 Sep 2024 | A Trial to Learn if Single Ascending Intravenous (IV) Doses of REGN7508 Are Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants | |
| Phase 1Completed | 7 Apr 2025 | Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026